Autocrine and paracrine regulation by cytokines and growth factors in melanoma

Cytokine

Volumn 12, Issue 6, 2000, Pages 547-554

  Lázár Molnár, Eszter ^a   Hegyesi, Hargita ^a   Tóth, Sára ^a   Falus, András ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Autocrine; Cytokines; Growth factor; Melanoma; Paracrine

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

GENE EXPRESSION; GENE INACTIVATION; MELANOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0342646934     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0614     Document Type: Review

References (51)

1. Shih I, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol. 100:1993;S196-S203.
2. Rodeck U. Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metast Rev. 12:1993;219-226.
3. Györfi T, Herlyn M. Melanocyte and melanoma cell lines. Hay RJ, Park J-G, Gazdar A. Atlas of Human Tumour Cell Lines. 1994;413-427 Academic Press, San Diego.
4. Krasagakis K, Garbe C, Orfanos CE. Cytokines in human melanoma cells: synthesis, autocrine stimulation and regulatory functions - an overview. Melanoma Res. 3:1993;425-433.
5. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M. Constitutive expression of multiple growth factor genes by melanoma cells but not by normal melanocytes. J Invest Dermatol. 97:1991;20-26.
6. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 120:1993;1281-1288.
7. Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, Moellmann G, McGuirre J. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol. 107:1988;1611-1619.
8. Yayon A, Ma Y-S, Safran M, Klagsbrun M, Halaban R. Suppression of autocrine cell proliferation and tumourigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase deficient FGF receptor 1: evidence for the involvement of Src-family kinases. Oncogene. 14:1997;2999-3009.
9. Albino PA, Davis BM, Nanus DM. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 51:1991;4815-4820.
10. Xerri L, Battyani Z, Grob J-J, Parc P, Hassoun J, Bonerandi J-J, Birnbaum D. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res. 6:1996;223-230.
11. Rodeck U, Herlyn M. Growth factors in melanoma. Cancer Metast Rev. 10:1991;89-101.
12. Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R. Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol. 109:1989;3115-3128.
13. Miglarese MR, Halaban R, Gibson NG. Regulation of fibroblast growth factor 2 expression in melanoma cells by the c-MYB proto-oncoprotein. Cell Growth Differ. 8:1997;1199-1210.
14. Barnhill RL, Xiao M, Graves D, Antoniades HN. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Brit J Dermatol. 135:1996;898-904.
15. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe C, Kari CS. Transforming growth factor β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:1994;575-581.
16. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Gianotti B. In situ expression of transforming growth factor β is associated with melanoma progression and correlates with Ki67, HLA-DR and β3 integrin expression. Melanoma Res. 7:1997;313-321.
17. Vetterlein M, Kammerer B, Kokoschka EM, Micksche M. Differential ways of escape from negative growth control by TGF-β1 in premature and mature melanoma cells. Melanoma Res. 5:1995;28.
18. Morinaga Y, Fujita N, Ohishi K, Tsuruo T. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-β and tumour cell factors. Int J Cancer. 71:1997;422-428.
19. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumour progression. J Leukocyte Biol. 62:1997;588-597.
20. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM. IL-8 is produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol. 151:1993;2667-2675.
21. Nakai S, Mizuno K, Kaneta M, Hirai Y. A simple, sensitive bioassay for the detection of interleukin-1 using human melanoma A375 cell line. Biochem Bioph Res Co. 154:1988;1189-1196.
22. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer. 56:1994;853-857.
23. Itoh S, Hayashi H, Watanabe N, Kobayashi Y, Takii T, Onozaki K. Interleukin 1 (IL-1) production is not essential for acquired resistance of human A375 melanoma cells to anti-proliferative effect of IL-1. Int J Cancer. 65:1996;805-811.
24. Sun WH, Kreisle RA, Phillips AW, Ershler WB. In vivo and in vitro characteristics of interleukin-6-transfected B16 melanoma cells. Cancer Res. 52:1992;5412-5415.
25. Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP. Down-regulation of interleukin-6 receptor α chain in interleukin-6 transduced melanoma cells causes selective resistance to interleukin-6 but not to oncostatin M. Cancer Res. 55:1995;2200-2205.
26. Oh JW, Katz A, Harroch S, Eisenbach L, Revel M, Chebath J. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumour cells. Oncogene. 15:1997;569-577.
27. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. J Immunol. 139:1987;2977-2983.
28. Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A, Gascan H. Signaling of type II oncostatin M receptor. J Biol Chem. 272:1997;15760-15764.
29. Heymann D, Blanchard F, Raher S, De Groote D, Godard A. Modulation of LIF expression in human melanoma cells by Oncostatin M. Immunol Lett. 46:1995;245-251.
30. Lu C, Rak JW, Kobayashi H, Kerbel RS. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res. 53:1993;2708-2711.
31. Chen Q, Daniel V, Maher W, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosupression mediated by melanoma. Int J Cancer. 56:1994;755-760.
32. Feng YY, Dummer R, Geersten R, Hofbauer G, Laine E, Manolio S, Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 71:1997;630-637.
33. Loir B, Bouchard B, Morandini R, Del Marmol V, Deraemaecker R, Garcia-Borron JC, Ghanem G. Immunoreactive α-melanotropin as an autocrine effector in human melanoma cells. Eur J Biochem. 244:1997;923-930.
34. FAKphosphorylation. Exp Cell Res. 237:1997;19-28.
35. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkinson WO. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature. 371:1994;799-802.
36. Siegrist W, Willard DH, Wilkinson WO, Eberle AN. Agouti protein inhibits growth of B16 melanoma cells in vitro by acting through melanocortin receptors. Biochem Biophys Res Co. 218:1996;171-175.
37. Blesch A, Bosserhoff AK, Apfel R, Behl K, Hessdoerfer B, Schmidt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 54:1994;5695-5701.
38. Bosserhof AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57:1997;3149-3153.
39. Silletti S, Timar J, Honn KV, Raz A. Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants. Cancer Res. 54:1994;5752-5756.
40. Nagai Y, Ishikawa O, Miyachi Y, Watanabe H. Expression of autocrine motility factor receptor in cutaneous malignant melanoma. Dermatology. 192:1996;8-11.
41. Fleming MG, Howe SF, Graf LH. Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas. Am J Dermatopath. 16:1994;383-391.
42. Resnicoff M, Coppola D, Sell C, Rubin C, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor. Cancer Res. 54:1994;4848-4850.
43. Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem. 264:1989;21544-21549.
44. Bröcker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve growth factor in tumours of melanocyte origin. J Invest Dermatol. 96:1991;662-665.
45. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 391:1998;298-301.
46. 2+-mobilizing H1 receptors. J Cell Biol. 110:1990;1211-1215.
47. Reynolds JL, Akhter J, Morris DL. In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. Melanoma Res. 6:1996;95-99.
48. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. British J Cancer. 76:1997;930-934.
49. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, Seymour LW. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Co. 217:1995;721-727.
50. Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol. 8:1996;167-174.
51. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph S, J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ J Biol Chem. 272:1997;28779-28785.